Artivion (NYSE:AORT) Cut to “Hold” at Wall Street Zen

Artivion (NYSE:AORT) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

AORT has been the subject of a number of other research reports. Citizens Jmp upped their price objective on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artivion in a research note on Wednesday, January 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $58.00 price objective on shares of Artivion in a research note on Monday, February 2nd. Oppenheimer reiterated an “outperform” rating and issued a $50.00 price objective on shares of Artivion in a report on Friday, November 7th. Finally, Canaccord Genuity Group lowered their target price on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $48.69.

Artivion Stock Performance

Shares of NYSE AORT opened at $36.24 on Friday. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of 181.18 and a beta of 1.59. The company has a current ratio of 3.93, a quick ratio of 2.88 and a debt-to-equity ratio of 0.50. Artivion has a 1-year low of $21.97 and a 1-year high of $48.25. The stock’s 50-day moving average is $43.60 and its 200 day moving average is $42.79.

Artivion (NYSE:AORT) last released its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. Artivion had a return on equity of 7.74% and a net margin of 2.21%.The company had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. The company’s revenue was up 19.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Artivion will post 0.37 EPS for the current fiscal year.

Insider Activity at Artivion

In other Artivion news, CEO James P. Mackin sold 30,921 shares of the business’s stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $45.56, for a total transaction of $1,408,760.76. Following the transaction, the chief executive officer directly owned 800,993 shares of the company’s stock, valued at approximately $36,493,241.08. The trade was a 3.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Marshall S. Stanton sold 47,376 shares of the firm’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $45.04, for a total transaction of $2,133,815.04. Following the completion of the sale, the senior vice president directly owned 44,753 shares of the company’s stock, valued at approximately $2,015,675.12. This represents a 51.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 128,448 shares of company stock worth $5,793,361 over the last 90 days. 7.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Artivion

Hedge funds and other institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd bought a new stake in Artivion during the 3rd quarter valued at approximately $27,000. Aster Capital Management DIFC Ltd lifted its stake in shares of Artivion by 402.3% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after purchasing an additional 519 shares during the period. Larson Financial Group LLC boosted its position in shares of Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after purchasing an additional 563 shares in the last quarter. USA Financial Formulas grew its stake in Artivion by 163.5% in the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after purchasing an additional 703 shares during the period. Finally, KBC Group NV purchased a new stake in Artivion in the fourth quarter worth $65,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Key Headlines Impacting Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q4 beat — Artivion reported Q4 EPS of $0.17 versus the $0.14 consensus and revenue of $118.3M (above estimates), with quarterly revenue up ~19% year-over-year. This confirms continued top-line momentum. Read More.
• Positive Sentiment: Full-year revenue growth — GAAP revenue rose to $441.3M for FY2025 from $388.5M in FY2024, signaling sustained recovery/expansion in sales. Read More.
• Positive Sentiment: FY2026 revenue guidance modestly above street — management guided revenue to $486.0M–$504.0M (consensus ~$491.1M), which implies a midpoint slightly ahead of estimates and supports continued top-line growth. Read More.
• Neutral Sentiment: Earnings call materials/transcript posted — the full Q4 earnings call transcript and slide deck are available for detail on segment performance and cadence. Useful for investors wanting management color. Read More.
• Negative Sentiment: Analyst price-target trim — Canaccord cut its AORT price target from $51 to $48 while keeping a “buy” rating; the cut reduces near-term analyst upside and may have pressured sentiment. Read More.
• Negative Sentiment: EPS guidance unclear/omitted — the company’s release/summary lacked clear EPS guidance (the EPS figure was not provided in the guidance summary), which can create uncertainty even with revenue guidance in place. Read More.
• Negative Sentiment: Large-volume sell-off — shares moved lower on unusually high volume versus average, indicating stronger selling pressure that amplified the price reaction to mixed news. Read More.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.